BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12930682)

  • 1. [A survey of the long-term incidence rate of benign prostate hyperplasia after vasectomy].
    Nie Y; Guo XK; Gao WY; Zhang Y; Li WL; Cheng QX; Bian J; Wang Y; Zhou CG; Cheng SP
    Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1303-5. PubMed ID: 12930682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
    Xu J; Qian WQ; Song JD
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries.
    Fourcade RO; Théret N; Taïeb C;
    BJU Int; 2008 May; 101(9):1111-8. PubMed ID: 18279447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
    Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
    BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of contact laser versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia with small or moderately enlarged prostates.
    Tuhkanen K; Heino A; Aaltomaa S; Ala-Opas M
    Scand J Urol Nephrol; 2003; 37(6):487-93. PubMed ID: 14675922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple case definition of clinical benign prostatic hyperplasia, based on International Prostate Symptom Score, predicts general practitioner consultation rates.
    Kok ET; Bohnen AM; Jonkheijm R; Gouweloos J; Groeneveld FP; Thomas S; Bosch JL
    Urology; 2006 Oct; 68(4):784-9. PubMed ID: 17070353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
    Tsukamoto T; Masumori N; Rahman M; Crane MM
    Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
    Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
    Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transurethral resection of the prostate (TURP)--in the treatment of benign prostatic hypertrophy (BPH) in Mekelle, Ethiopia.
    Alemu MH
    Ethiop Med J; 2009 Jan; 47(1):65-9. PubMed ID: 19743783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quality of life assessment of the male with benign prostate hypertrophy].
    Nekić VC; Tiljak H; Petricek G; Soldo D; Nekić G; Buljan N
    Acta Med Croatica; 2007 Feb; 61(1):49-55. PubMed ID: 17593641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between lower urinary tract symptoms and objective measures of benign prostatic hyperplasia: a Chinese survey.
    Wang JY; Liu M; Zhang YG; Zeng P; Ding Q; Huang J; He DL; Song B; Kong CZ; Pang J
    Chin Med J (Engl); 2008 Oct; 121(20):2042-5. PubMed ID: 19080272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Data analysis of the objective observation parameters of benign prostatic hyperplasia patients accepting different treatment regimens].
    Zhang YG; Wang JY; Liu M; Wan B; Wei D; Deng SM; Xu J; Wu JY; Chu X; Zeng P
    Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1690-2. PubMed ID: 19024540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM
    BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of transurethral resection of prostate on quality of life in aged patients with benign prostatic hyperplasia].
    Cheng NZ; Tang ZY; Liu Y; Liu XS; Qi L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Oct; 33(10):975-8. PubMed ID: 19001744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short term outcomes of high power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate.
    Volkan T; Ihsan TA; Yilmaz O; Emin O; Selcuk S; Koray K; Bedi O
    Eur Urol; 2005 Oct; 48(4):608-13. PubMed ID: 16135396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.